Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 14/20 | 0.64 |
| ▸ | PROKR1 | Q8TCW9 | 14/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | CCR3 | P51677 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222003 | 0.85 | HTR2C (0.62) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL3221859 | 0.79 | MEN1 (0.60) | FPR2PROKR1MEN1KMT2ALMNA | |
| SCHEMBL3210439 | 0.79 | MEN1 (0.57) | MEN1KMT2APTGDRLMNAMAPT | |
| SCHEMBL15549468 | 0.78 | FPR2 (1.00) | FPR2PROKR1MEN1KMT2AMMP13 | |
| SCHEMBL3223466 | 0.78 | HSD11B1 (0.55) | FPR2PROKR1MEN1KMT2ALMNA | |
| SCHEMBL3213292 | 0.78 | MAPT (0.60) | MEN1KMT2APTGDRLMNAMAPT | |
| SCHEMBL15549418 | 0.78 | FPR2 (1.00) | FPR2PROKR1 | |
| SCHEMBL15548957 | 0.78 | FPR2 (1.00) | FPR2PROKR1 | |
| SCHEMBL15548446 | 0.78 | FPR2 (1.00) | FPR2PROKR1MMP13 | |
| SCHEMBL15550083 | 0.78 | FPR2 (1.00) | FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | FPR2 3918/4885PROKR1 1585/4885HRH1 2648/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | FPR2 3342/4885PROKR1 1345/4885HRH1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.